Hill-Rom Holdings Inc (NYSE:HRC) released its quarterly earnings results on Friday. The medical technology company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05, Bloomberg Earnings reports. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The firm had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. During the same quarter in the prior year, the firm earned $1.18 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Hill-Rom Holdings updated its Q1 guidance to $0.77-0.79 EPS and its FY18 guidance to $4.22-4.30 EPS.
Shares of Hill-Rom Holdings (HRC) opened at $77.50 on Friday. The firm has a market cap of $5,104.46, a P/E ratio of 20.07, a PEG ratio of 1.60 and a beta of 1.19. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.33 and a current ratio of 1.76.
TRADEMARK VIOLATION WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/05/hill-rom-holdings-inc-hrc-releases-quarterly-earnings-results-beats-estimates-by-0-05-eps.html.
HRC has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Hill-Rom Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. BidaskClub downgraded shares of Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Needham & Company LLC reduced their price target on shares of Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, July 28th. Cantor Fitzgerald set a $86.00 price target on shares of Hill-Rom Holdings and gave the stock a “hold” rating in a research report on Friday, July 28th. Finally, Stifel Nicolaus restated a “buy” rating and set a $84.00 price target on shares of Hill-Rom Holdings in a research report on Sunday, July 30th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $87.29.
In other Hill-Rom Holdings news, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $77.48, for a total value of $532,287.60. Following the completion of the sale, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,293,993.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total transaction of $306,689.60. Following the completion of the sale, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,300,005.84. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
What are top analysts saying about Hill-Rom Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hill-Rom Holdings Inc and related companies.